which is heading for phase 2 trials in cardiomyopathy associated with ATTR amyloidosis, a life-threatening disease affecting the heart and nervous system. Novo Nordisk also gets rights to the ...

Novo Nordisk has reached an agreement to buy Germany’s Cardior Pharmaceuticals for €1.025 billion ($1.1 billion), adding expertise in RNA therapeutics and a heart failure therapy in mid-stage ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...

The runaway success of GLP-1 drugs made Novo Nordisk, a Danish drugmaker ... They help fight diabetes, obesity, heart disease and possibly may have uses for other ailments. Steven Goldstein ...

Transthyretin amyloidosis (ATTR) is a condition caused by TTR protein misfolding and amyloid deposition, particularly in the ...

Novo Nordisk ... the risk of heart disease. Despite this success, recent market challenges and a decline in the company’s share price since mid-2024 prompted the Novo Nordisk Foundation Board ...

Also Read: Novo Nordisk ... disease (CVD) were seen. Reductions were also observed within six months in the risk of dying from CVD or being hospitalized or needing urgent medical attention due to ...

Prothena Corporation plc's phase 3 trial failure in AL Amyloidosis was a setback, but Alzheimer's & Parkinson's data could ...

They help fight diabetes, obesity, heart disease and possibly may have uses for other ailments. But the success of bringing these drugs to market has quickly worn off. Novo Nordisk's stock price ...

Medicare still covers the drugs for diabetes and heart disease. Novo Nordisk shares fell following the announcement. The company's shares have fallen more than 50% over the past year. Get the ...